General Information

Age Group

Adults

Status

Recruiting

Protocol Number

NCT06662786

Background Information

The purpose of this study is to compare the effects of two anticancer drugs (amivantamab and cetuximab) when each is given in combination with standard colorectal cancer (CRC) chemotherapy (FOLFIRI, mFOLFOX6) to participants with metastatic CRC that lack mutations in genes called KRAS/NRAS and BRAF. Cetuximab, FOLFIRI and mFOLFOX6 are already used to treat participants with this type of cancer.

For more information, visit https://clinicaltrials.gov/study/NCT06662786

Offered At

Inova Schar Cancer Institute
A division of Inova Fairfax Hospital
8081 Innovation Park Drive 
Fairfax, VA 22031
Principal Investigator

Timothy Cannon, MD

Eligibility Information

  • 18 years of age or older
  • Histologically or cytologically confirmed adenocarcinoma of the left-sided colorectal cancer
  • Unresectable or metastatic disease
  • Have KRAS, NRAS, and BRAF Wild Type tumor
  • Have measurable disease according to RECIST v1.1
  • Has not received any prior systemic therapy for unresectable or metastatic CRC
  • Have an ECOG PS of 0 or 1
  • Renal and Hepatic function within normal ranges
  • Other inclusion criteria in protocol

Ineligibility Information

  • Pregnancy
  • Breastfeeding
  • Carcinoma of the anal canal
  • Brain metastises
  • Uncontrolled diabetes mellitus
  • Significant history of bleeding events
  • Allergies to amivantamab, mFOLFOX6 (any component), FOLFIRI (any component)
  • History of significant cardiovascular events
  • Prior exposure to any agents that target EGFR or MET
  • Additional exclusion criteria in protocol